Global Tuberculosis Vaccination Market Growth 2025-2031

The global Tuberculosis Vaccination market size is predicted to grow from US$ 80.7 million in 2025 to US$ 97 million in 2031; it is expected to grow at a CAGR of 3.1% from 2025 to 2031.

Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme

The tuberculosis (TB) vaccination market is driven by the global efforts to combat TB and the increasing burden of the disease in high-risk populations. TB is a highly contagious bacterial infection that poses a significant public health challenge worldwide. Vaccination against TB, primarily through the Bacille Calmette-Guérin (BCG) vaccine, is essential in reducing TB incidence and severity, especially in endemic regions. The rise in TB cases and drug-resistant strains contribute to market growth as governments and healthcare organizations focus on prevention strategies. Moreover, advancements in vaccine research and development, including novel TB vaccines under investigation, have the potential to further improve TB control efforts. However, the market also faces challenges, including the variable efficacy of the BCG vaccine against different forms of TB and the need for improved vaccine coverage in high-burden areas. Additionally, addressing vaccine supply and distribution challenges and ensuring equitable access to TB vaccination can pose obstacles for comprehensive disease control. To succeed, companies must focus on research and development to offer innovative TB vaccine candidates, collaborate with global health initiatives to promote vaccination campaigns, and address the challenges to meet the increasing demand for effective TB prevention solutions.

LP Information, Inc. (LPI) ' newest research report, the “Tuberculosis Vaccination Industry Forecast” looks at past sales and reviews total world Tuberculosis Vaccination sales in 2024, providing a comprehensive analysis by region and market sector of projected Tuberculosis Vaccination sales for 2025 through 2031. With Tuberculosis Vaccination sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Tuberculosis Vaccination industry.

This Insight Report provides a comprehensive analysis of the global Tuberculosis Vaccination landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tuberculosis Vaccination portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Tuberculosis Vaccination market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tuberculosis Vaccination and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tuberculosis Vaccination.

This report presents a comprehensive overview, market shares, and growth opportunities of Tuberculosis Vaccination market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Immune Vaccine
Therapy Vaccine

Segmentation by Application:
Self-Procurement
UNICEF
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC – Institute of Vaccines and Medical Biologicals
Queen Saovabha Mem. Inst
Microgen

Key Questions Addressed in this Report

What is the 10-year outlook for the global Tuberculosis Vaccination market?

What factors are driving Tuberculosis Vaccination market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Tuberculosis Vaccination market opportunities vary by end market size?

How does Tuberculosis Vaccination break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.